| Filed On | Filing |
|---|---|
| 13 Oct 2026 |
8-K: Other Events
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes |
| 07 Jul 2026 |
8-K: Regulation FD Disclosure
MIAMI, July 7, 2026 – Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-th... |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares of common stock entitled to vote at the Annual Meeting was 77,966,409, ... |
| 04 May 2026 |
8-K: Entry into a Material Definitive Agreement
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL |
| 22 Apr 2026 |
8-K: Regulation FD Disclosure
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 |
| 19 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
BARCLAYS CAPITAL INC.As Representatives of the several Underwriters |
| 10 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Results demonstrated early signals of C-peptide preservation |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Corporate Presentation January 2026 Modifying Disease Delaying Progression Transforming Treatment Company Logo © 2026 SAB BIOTHERAPEUTICS, INC. Exhibit 99.1 |
| 07 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
MIAMI, Jan. 7, 2026 -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today anno... |
| 29 Dec 2025 |
8-K: Other Events
On December 29, 2025, SAB Biotherapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with UBS Securities LLC (the “Agent”) with respect to an at-the-market offering program under which the Company may offer an... |
| 30 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned as members of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”) and the size of the Board was decreased from 11 to nine, in accordanc... |
| 26 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1.1 Effective Date of the Plan. The Board of Directors of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) originally adopted the SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”) effective as of ... |
| 21 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 21, 2025, is entered into by and among SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to th... |
| 17 Jul 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On July 17, 2025, SAB Biotherapeutics, Inc. (the “Company” or “SAB”), held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares of common stock entitled to vote at the Annual Meeting was 9,291,697, a... |
| 05 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL |
| 28 Jan 2025 |
8-K: Other Events
SAB BIO INNOVATION DAY ACCELERATING DISEASE-MODIFYING TREATMENTS IN AUTOIMMUNITY January 28, 2025 (Nasdaq: SABS) EXHIBIT 99.2 |
| 09 Sep 2024 |
8-K: Regulation FD Disclosure
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting |
| 31 Jul 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Employment Agreement (the “Agreement”) is dated July 26, 2024 (the “Effective Date”), by and between SAB BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and Lucy To (the “Executive”). |
| 27 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 27, 2024, SAB Biotherapeutics, Inc., doing business as SAB BIO (the “Company” or “SAB”), held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares of common stock entitled to vote at the Annu... |
| 31 May 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAB Biotherapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: |
Loading...